- Report
- February 2024
- 120 Pages
Global
From €4088EUR$4,275USD£3,503GBP
€4542EUR$4,750USD£3,892GBP
- Report
- April 2023
- 110 Pages
Global
From €4088EUR$4,275USD£3,503GBP
€4542EUR$4,750USD£3,892GBP
- Report
- April 2023
- 119 Pages
Global
From €4088EUR$4,275USD£3,503GBP
€4542EUR$4,750USD£3,892GBP
- Report
- July 2023
- 290 Pages
Global
From €3442EUR$3,600USD£2,950GBP
- Report
- April 2023
- 326 Pages
Global
From €3442EUR$3,600USD£2,950GBP
- Report
- January 2024
Global
From €2821EUR$2,950USD£2,417GBP
- Report
- October 2023
- 138 Pages
North America
From €4207EUR$4,400USD£3,605GBP
- Report
- November 2020
- 450 Pages
Global
From €4686EUR$4,900USD£4,015GBP
- Report
- September 2020
- 700 Pages
Global
From €4686EUR$4,900USD£4,015GBP
- Report
- February 2022
- 84 Pages
Global
From €1242EUR$1,299USD£1,064GBP
- Report
- November 2022
- 154 Pages
Global
From €4781EUR$5,000USD£4,097GBP
- Report
- March 2024
Global
From €400EUR$448USD£355GBP
- Report
- June 2022
- 1500 Pages
Global
From €3729EUR$3,900USD£3,196GBP
- Drug Pipelines
- March 2022
- 900 Pages
Global
From €8606EUR$9,000USD£7,375GBP
- Report
- February 2022
- 360 Pages
United States
From €3442EUR$3,600USD£2,950GBP
- Report
- November 2021
- 222 Pages
Global
From €2869EUR$3,000USD£2,458GBP
- Report
- March 2021
- 240 Pages
United States
From €2869EUR$3,000USD£2,458GBP
- Report
- June 2020
- 753 Pages
Global
From €3156EUR$3,300USD£2,704GBP
- Report
- February 2020
- 600 Pages
Global
From €3825EUR$4,000USD£3,278GBP
- Report
- August 2022
- 148 Pages
Global
From €5259EUR$5,500USD£4,507GBP
Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers.
Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated.
Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more